Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a sleep drug curb impulsivity in opioid recovery?

NCT ID NCT06981195

Recruiting now Symptom relief Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether the insomnia medication lemborexant can improve sleep, mood, and impulse control in men and women with opioid use disorder who are already taking buprenorphine. Participants take either lemborexant or a placebo nightly for 8 weeks and complete surveys, computer tests, and sleep tracking. The goal is to see if treating insomnia can also reduce impulsive behavior and support recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lemborexant
What this could lead to
If it works, this could point toward a way to improve sleep and reduce impulsive behavior in people recovering from opioid use disorder.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. The drug may not improve sleep or impulsivity more than a placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia opiate dependence opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA OPIOID USE OPIOID USE DISORDER OREXIN ANTAGONIST

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • VCU Institute for Drug and Alcohol Studies

    RECRUITING

    Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.